Health Blueprint

Back to Longevity News

News summary

Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

Source: PR Newswire • Published: 02 Nov 2026, 21:15

Summarized by Masters of Longevity from PR Newswire.

Eloxx will present its exaluren ribosomal readthrough program on November 9, 2026.

Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
Key Takeaways
  • Eloxx is presenting at the Guggenheim conference on November 9.
  • Exaluren is being developed for nonsense-mutation kidney diseases.
  • Licensing of ZKN-013 to Almirall was reported by the company.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.